Maia Biotechnology Inc (MAIA)

MAIA............................https://stockcharts.com/sc3/ui/?s=MAIA&p=w&b=5&g=0&id=p86431144783

I'm not buying MAIA. ( also not shorting )
MAIA needs $ to run their P 3 trial . They need someone like Great Point Partners ...around $1.b in AUM and also invested to RZLT and UNCY ...to come in and fund their P 3 trial .
But doubt Great Point or any of the other biotech hedge fund specialists will fund this Co ...why ?...because board of directors have authorized the use of cash on hand to trade crypto IIRC ..plus awarded themselves some very generous options that vest on limited requirements ( like achieving certain milestones )
Lot of red flags here when you do some detailed DD
JMO
Good luck
Kiwi

So how much are you buying then in the $3 range ?

Well while waiting for the FDA update on UNCY ...did some more DD on MAIA and can see why its fast tracked and has an NIH grant

Efficacy Highlights (180 mg Dose)
As of the mid-2025 data cutoffs, the 180 mg dose sequenced with cemiplimab demonstrated:
Progression-Free Survival (PFS): An estimated median PFS of 5.6 months. This is more than double the historical standard-of-care (SOC) threshold of approximately 2.5 months for this population.
Overall Survival (OS): An estimated median OS of 17.8 months across third-line patients, with high confidence levels (95% CI lower bound of 12.5 months). This significantly exceeds the typical SOC survival of 5–8 months.
Response Rates: An Overall Response Rate (ORR) of 38% and a Disease Control Rate (DCR) of 85% in the 3L setting. For comparison, typical SOC chemotherapy ORRs in similar settings are roughly 6–10%.
Durability: Some patients have completed over 33 cycles of therapy, indicating long-term benefit and potential for extended dosing.
Safety & Mechanism
Tolerability: The 180 mg dose was chosen for its superior safety profile compared to the 360 mg dose, with most adverse events being Grade 1 or 2 (mild to moderate).
Biomarker Activity: Treatment at this dose level induced a 1.73-fold increase in telomere dysfunction-induced foci (TIFs), confirming that ateganosine is successfully targeting telomeres in cancer cells as intended.
The positive results from this 180 mg cohort are the primary driver for the Part C expansion and the upcoming Phase 3

Enrolling 300 patients in a Phase 3 oncology trial like THIO-104 is a major financial undertaking, typically costing between $20 million and $60 million in total, depending on trial complexity and geographical distribution.


Now they just need $ to complete a P 3 trial which requires them to enroll 300 patients ......or best case scenario..enough for a successful interim analysis which probably requires around 200 enrolled. .
These guys are burning cash as they set up these clinical trial sites
Good luck
Kiwi

MAIA..........................................https://stockcharts.com/sc3/ui/?s=MAIA&p=w&b=5&g=0&id=p86431144783

So just so you know what you're into here
Looking at the Sept 25 10Q
Cash on hand at the end of that Qt was $11m ...and the Co is losing $9m a qt .
They have started a P 3 trial that will run to the end of 2031 and enroll 300 patients . IMHO they have nowhere near the funds needed to run this trial.
Meanwhile , recently a key director and mgt appear to be awarding themselves huge stock options ...for free .. that are exercisable in 5 mths , maybe for some sooner .
Mgt owns a lot of stock because IMHO knowledgeable hedge funds / mutual funds aren't interested in.
JMO
Kiwi

Another new 52 week high…..check out the insiders trading….large percentage of shares own by Maia executives….💰💵

No risk = no reward sometimes…..didn’t you think of that when you got back in RZLT when it lost 90% of its sp a couple months ago?

From a Quick Look . Co doesnt have the funds to complete a P 3 trial and FDA is unlikely to grant priority review until the P 3 is mostly enrolled.
Co appears to be using cash on hand to trade crypto as a way to raise $ .
WAY to risky for me
Good luck
Kiwi

Starting to make another run up 💵💰

Wonder if Maia is a buyout possibility

Looking forward for fda approval

2026 should be. Rewarding year

Sp up nicely this week

MAIA...........................................https://stockcharts.com/sc3/ui/?s=MAIA&p=w&b=5&g=0&id=p86431144783

MAIA...................................https://stockcharts.com/sc3/ui/?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA.................................................https://stockcharts.com/sc3/ui/?s=MAIA&p=W&b=5&g=0&id=p86431144783

MAIA....................................https://stockcharts.com/sc3/ui/?s=MAIA&p=W&b=5&g=0&id=p86431144783

... $1.51 “The posters showcased at ESMO 2025 featured exceptional extended survival in third-line NSCLC patients. In addition, as of September 17, 2025, a patient that began therapy in March 2023 has shown survival of 30 months, or 912 days, an outstanding measure relative to many of the high-risk cancers,” said MAIA CEO Vlad Vitoc, M.D. “Very few options exist for patients who are refractory or resistant to immune checkpoint inhibitors (ICI). We believe that a survival of over two years is a clear signal of ateganosine’s role in effectively targeting and eliminating NSCLC tumor cells.”

MAIA recent 52 week low

MAIA, recent 52 week low

maia.............................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

no imetelstat....
promise partnership q2 2024 and dont deliver?

Its a supply agreement - no biobucks

I believe its a scam

if the insiders werent buying common stock i would be so sure this is another Theranos. Complete flim flam

New offering just raised 2.44 million …..and the share price acted positively

Hard to tell.

The company had almost $12m in cash at the end of the last quarter, and had just under $4m in expenses last quarter.

The company also has an active ATM, that they stated would likely be active through end of this quarter.

Given all that, probably not a new offering but any pop will get diluted via their ATM.

Murocman

MAIA under $4

Raise coming?

MAIA...HERE COMES 6 BUCKS

MAIA...HERE WE GO

MAIA MONSTER BIO

MAIA ANOTHER BIO BEAST SETTING UP ON THE WEEKLY!!

CHICAGO--(BUSINESS WIRE)--May 16, 2024--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract about its Phase 2 THIO-101 clinical trial named “A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results” was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, to take place May 31-June 4, 2024, in Chicago, Illinois. The poster is scheduled for presentation on June 3, 2024, from 1:30pm to 4:30pm CST.

“We are proud to accept ASCO’s invitation to present at its 2024 Annual Meeting, the most significant gathering of oncology professionals worldwide,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “We look forward to revealing the newest efficacy results from THIO-101 and discussing our pioneering telomere targeting science underlying THIO, the first and only cancer treatment of its kind in clinical development.”

MAIA’s abstract will be available online at the ASCO Annual Meeting 2024 website during the week prior to the conference start date, and the poster will be published on maiabiotech.com on the day of the presentation, June 3, 2024.

MAIA under $

Pricing now at a 52 week high, which is going against the bearish trend in the medtech sector which peaked in February
This is a good thing

MAIA no longer under 3$

I wouldn’t be surprised with all the form 4s. I think there’s still a lot of legwork to be done via trials to unlock value here, but a partner would be nice. All those form 4s though seem to be essentially raising funds, so I’m not sure a partner is quite there yet. We’ll see. I just started a position here in late Feb, wish I had built up more before this run.

Have ASCO on watch :)
I believe partner is coming q2.

Lot of potential, looking forward to continued data readouts.

I believe MAIA can go to 4-20bln mcap. Look at the recent presentation @bs3500.

More boom than we’ve had?

will go boom soon

MAIA......................https://stockcharts.com/h-sc/ui?s=MAIA&p=W&b=5&g=0&id=p86431144783

3/22 news On March 11, 2024, MAIA entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,043,587 shares of the Company’s common stock, and warrants to purchase up to 2,043,587 shares of the Company’s common stock, at a price per share of $1.17. The combined gross proceeds from the private placement, closed on March 14, 2024, were approximately $2.9 million, prior to deducting offering expenses payable by the Company.

Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer, commented, “The participation in our private placement from five of our independent directors points to their confidence in the science and clinical pathways for our immuno-oncology therapies targeting difficult-to-treat cancers.”

Stan V. Smith, Ph.D., added, “I have participated in every round of financing and I am a big believer in MAIA’s telomere-targeting approach to cancer and its potential to disrupt the field of research and development for cancer therapies, for the benefit of all humankind.”

Dr. Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

MAIA no longer under $2

MAIA 10Q due 3/22

$MAIA Thank you. I bought 1.52 blockbuster news...
https://ih.advfn.com/stock-market/AMEX/maia-biotechnology-MAIA/stock-news/93435486/maia-biotechnology-announces-strong-efficacy-of-th

https://ih.advfn.com/stock-market/AMEX/maia-biotechnology-MAIA/stock-news/93435486/maia-biotechnology-announces-strong-efficacy-of-th